Skip to main content
Top
Published in: BMC Gastroenterology 1/2018

Open Access 01-12-2018 | Research article

Metabolic syndrome and biochemical changes among non-alcoholic fatty liver disease patients attending a tertiary care hospital of Nepal

Authors: Bashu Dev Pardhe, Shreena Shakya, Anjeela Bhetwal, Jennifer Mathias, Puspa Raj Khanal, Roshan Pandit, Jyotsna Shakya, Hari Om Joshi, Sujan Babu Marahatta

Published in: BMC Gastroenterology | Issue 1/2018

Login to get access

Abstract

Background

Non-alcoholic fatty liver disease (NAFLD) is mutually and bidirectionally linked with metabolic syndrome (MetS) of which it is both the cause and the consequences. Worldwide, 6.3 to 33% of the general populations are estimated to suffer from the disease with even higher prevalence in the group sharing metabolic co-morbidities. Hence, this study aims to recognize various risk factors including metabolic components and blood parameters to predict the possible incidence of the disease.

Methods

Total of 429 (219 NAFLD and 210 control) subjects were conveniently selected for study during the period of 9 months. Diagnosis of non-alcoholic fatty liver disease was done by liver imaging and based on liver enzymes. Assessment of metabolic syndrome was done by International Diabetic Federation (IDF) and National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria. All biochemical and hematological parameters and liver enzymes were estimated by using standard guideline. Mean comparison of quantitative data in different groups were performed using analysis of variance (one-way ANOVA). Risk estimation of NAFLD associated with each character was verified by Chi-square test.

Results

There was significant high levels of body mass index (BMI), waist circumference (WC) and lipid profiles in NAFLD patients in comparison to control population (p < 0.001). Further, according to the NCEP ATP III criteria, 13.6% of NAFLD were present with MetS where risk estimate was significant (OR = 2.15). Whereas, other criteria (IDF) for MetS showed higher frequency (30.1%) with higher risk (OR = 29.75) for the presence of MetS in NAFLD patients. The change in triglycerides (TG) and HDL-C (high density lipoprotein cholesterol) was also statistically significant in different grades of NAFLD. High risk for NAFLD was associated with existing co-morbid conditions like cardiovascular risk patients (3.18 times) followed by obese patients (1.72 times) and Diabetes Mellitus patients (1.68 times) at a significant level.

Conclusion

The result of this study suggests that there is an increased prevalence of all the components of MetS and significant changes in biochemical markers in cases of NAFLD. Timely diagnosis would help in delaying its complications and co-morbidities.
Literature
1.
go back to reference Santoshini A, Swathi P, Babu SR, Nair R. Estimation of lipid profile in various grades of non alcoholic fatty liver disease diagnosed on ultrasonography. Int J Pharm Bio Sci. 2016;7(3):1198–203. Santoshini A, Swathi P, Babu SR, Nair R. Estimation of lipid profile in various grades of non alcoholic fatty liver disease diagnosed on ultrasonography. Int J Pharm Bio Sci. 2016;7(3):1198–203.
2.
go back to reference Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol. 2018;68(2):335–52.CrossRefPubMed Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol. 2018;68(2):335–52.CrossRefPubMed
3.
go back to reference Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005–23.CrossRefPubMed Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005–23.CrossRefPubMed
5.
go back to reference Wang S, Zhang C, Zhang G, Yuan Z, Liu Y, Ding L, et al. Association between white blood cell count and non-alcoholic fatty liver disease in urban Han Chinese: a prospective cohort study. BMJ Open. 2016;6(6):e010342.CrossRefPubMedPubMedCentral Wang S, Zhang C, Zhang G, Yuan Z, Liu Y, Ding L, et al. Association between white blood cell count and non-alcoholic fatty liver disease in urban Han Chinese: a prospective cohort study. BMJ Open. 2016;6(6):e010342.CrossRefPubMedPubMedCentral
6.
go back to reference Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, Caldwell SH, et al. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig Liver Dis. 2015;47(12):997–1006.CrossRefPubMed Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, Caldwell SH, et al. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig Liver Dis. 2015;47(12):997–1006.CrossRefPubMed
7.
go back to reference Villegas R, Xiang Y-B, Elasy T, Cai Q, Xu W, Li H, et al. Liver enzymes, type 2 diabetes, and metabolic syndrome in middle-aged, urban Chinese men. Metab Syndr Relat Disord. 2011;9(4):305–11.CrossRefPubMedPubMedCentral Villegas R, Xiang Y-B, Elasy T, Cai Q, Xu W, Li H, et al. Liver enzymes, type 2 diabetes, and metabolic syndrome in middle-aged, urban Chinese men. Metab Syndr Relat Disord. 2011;9(4):305–11.CrossRefPubMedPubMedCentral
8.
go back to reference Tan C-E, Ma S, Wai D, Chew S-K, Tai E-S. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care. 2004;27(5):1182–6.CrossRefPubMed Tan C-E, Ma S, Wai D, Chew S-K, Tai E-S. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care. 2004;27(5):1182–6.CrossRefPubMed
9.
go back to reference Pokharel DR, Khadka D, Sigdel M, Yadav NK, Acharya S, Kafle RC, et al. Prevalence of metabolic syndrome in Nepalese type 2 diabetic patients according to WHO, NCEP ATP III, IDF and harmonized criteria. J Diabetes Metab Disord. 2014;13(1):104.CrossRefPubMedPubMedCentral Pokharel DR, Khadka D, Sigdel M, Yadav NK, Acharya S, Kafle RC, et al. Prevalence of metabolic syndrome in Nepalese type 2 diabetic patients according to WHO, NCEP ATP III, IDF and harmonized criteria. J Diabetes Metab Disord. 2014;13(1):104.CrossRefPubMedPubMedCentral
12.
go back to reference Bugianesi E, Rosso C, Cortez-Pinto H. How to diagnose NAFLD in 2016. J Hepatol. 2016;65(3):643. -4-4CrossRefPubMed Bugianesi E, Rosso C, Cortez-Pinto H. How to diagnose NAFLD in 2016. J Hepatol. 2016;65(3):643. -4-4CrossRefPubMed
13.
go back to reference Virk A, Steckelberg JM, editors. Clinical aspects of antimicrobial resistance. In: Mayo Clinic Proceedings: Elsevier; 2000.editors Virk A, Steckelberg JM, editors. Clinical aspects of antimicrobial resistance. In: Mayo Clinic Proceedings: Elsevier; 2000.editors
15.
go back to reference Nascimbeni F, Ballestri S, Machado MV, Mantovani A, Cortez-Pinto H, Targher G, et al. Clinical relevance of liver histopathology and different histological classifications of NASH in adults. Expert Rev. Gastroenterol. Hepatol. 2018;12(4):351–67. (just-accepted)CrossRefPubMed Nascimbeni F, Ballestri S, Machado MV, Mantovani A, Cortez-Pinto H, Targher G, et al. Clinical relevance of liver histopathology and different histological classifications of NASH in adults. Expert Rev. Gastroenterol. Hepatol. 2018;12(4):351–67. (just-accepted)CrossRefPubMed
16.
go back to reference Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Targher G, et al. Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases. Metab Clin Exp. 2017;72:57–65.CrossRefPubMed Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Targher G, et al. Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases. Metab Clin Exp. 2017;72:57–65.CrossRefPubMed
17.
go back to reference Siddiqui MS, Fuchs M, Idowu MO, Luketic VA, Boyett S, Sargeant C, et al. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile. Clin Gastroenterol Hepatol. 2015;13(5):1000–8.CrossRefPubMed Siddiqui MS, Fuchs M, Idowu MO, Luketic VA, Boyett S, Sargeant C, et al. Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile. Clin Gastroenterol Hepatol. 2015;13(5):1000–8.CrossRefPubMed
18.
go back to reference Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol. 2018;14(2):99–114.PubMed Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. Nat Rev Endocrinol. 2018;14(2):99–114.PubMed
19.
go back to reference Mantovani A, Gisondi P, Lonardo A, Targher G. Relationship between non-alcoholic fatty liver disease and psoriasis: a novel Hepato-dermal Axis? Int J Mol Sci. 2016;17(2):217.CrossRefPubMedPubMedCentral Mantovani A, Gisondi P, Lonardo A, Targher G. Relationship between non-alcoholic fatty liver disease and psoriasis: a novel Hepato-dermal Axis? Int J Mol Sci. 2016;17(2):217.CrossRefPubMedPubMedCentral
20.
go back to reference Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol. 2013;59(4):859–71.CrossRefPubMed Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, et al. From NAFLD in clinical practice to answers from guidelines. J Hepatol. 2013;59(4):859–71.CrossRefPubMed
21.
go back to reference Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123(5):1705–25.CrossRefPubMed Sanyal AJ. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123(5):1705–25.CrossRefPubMed
22.
go back to reference Guideline for Type 2 Diabetes. International diabetes federation. In: Brussels Belgium; 2012. Guideline for Type 2 Diabetes. International diabetes federation. In: Brussels Belgium; 2012.
24.
go back to reference Schumann G, Klauke R. New IFCC reference procedures for the determination of catalytic activity concentrations of five enzymes in serum: preliminary upper reference limits obtained in hospitalized subjects. Clin Chim Acta. 2003;327(1–2):69–79.CrossRefPubMed Schumann G, Klauke R. New IFCC reference procedures for the determination of catalytic activity concentrations of five enzymes in serum: preliminary upper reference limits obtained in hospitalized subjects. Clin Chim Acta. 2003;327(1–2):69–79.CrossRefPubMed
25.
go back to reference Chen C-H, Huang M-H, Yang J-C, Nien C-K, Yang C-C, Yeh Y-H, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol. 2006;40(8):745–52.CrossRefPubMed Chen C-H, Huang M-H, Yang J-C, Nien C-K, Yang C-C, Yeh Y-H, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of Taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults. J Clin Gastroenterol. 2006;40(8):745–52.CrossRefPubMed
26.
go back to reference Sanyal D, Mukherjee P, Raychaudhuri M, Ghosh S, Mukherjee S, Chowdhury S. Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes. Indian J Endocrinol Metab. 2015;19(5):597.CrossRefPubMedPubMedCentral Sanyal D, Mukherjee P, Raychaudhuri M, Ghosh S, Mukherjee S, Chowdhury S. Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes. Indian J Endocrinol Metab. 2015;19(5):597.CrossRefPubMedPubMedCentral
27.
go back to reference Mahaling DU, Basavaraj MM, Bika AJ. Comparison of lipid profile in different grades of non-alcoholic fatty liver disease diagnosed on ultrasound. Asian Pac J Trop Biomed. 2013;3(11):907–12.CrossRefPubMedCentral Mahaling DU, Basavaraj MM, Bika AJ. Comparison of lipid profile in different grades of non-alcoholic fatty liver disease diagnosed on ultrasound. Asian Pac J Trop Biomed. 2013;3(11):907–12.CrossRefPubMedCentral
28.
go back to reference Agarwal A, Jain V, Singla S, Baruah B, Arya V, Yadav R, et al. Prevalence of non-alcoholic fatty liver disease and its correlation with coronary risk factors in patients with type 2 diabetes. J Assoc Physicians India. 2011;59:351–4.PubMed Agarwal A, Jain V, Singla S, Baruah B, Arya V, Yadav R, et al. Prevalence of non-alcoholic fatty liver disease and its correlation with coronary risk factors in patients with type 2 diabetes. J Assoc Physicians India. 2011;59:351–4.PubMed
29.
go back to reference Esteghamati A, Jamali A, Khalilzadeh O, Noshad S, Khalili M, Zandieh A, et al. Metabolic syndrome is linked to a mild elevation in liver aminotransferases in diabetic patients with undetectable non-alcoholic fatty liver disease by ultrasound. Diabetol Meta. Syndr. 2010;2(1):65.CrossRef Esteghamati A, Jamali A, Khalilzadeh O, Noshad S, Khalili M, Zandieh A, et al. Metabolic syndrome is linked to a mild elevation in liver aminotransferases in diabetic patients with undetectable non-alcoholic fatty liver disease by ultrasound. Diabetol Meta. Syndr. 2010;2(1):65.CrossRef
30.
go back to reference Santhoshakumari T, Radhika G, Kanagavalli P. A Study of Anthropometric And Lipid Profile Parameters in Non-Alcoholic Fatty Liver Disease Patients Attending A Tertiary Care Hospital at Puducherry. Santhoshakumari T, Radhika G, Kanagavalli P. A Study of Anthropometric And Lipid Profile Parameters in Non-Alcoholic Fatty Liver Disease Patients Attending A Tertiary Care Hospital at Puducherry.
31.
go back to reference Taslima R, Zebunnesa Z, Rahelee Z. Core components of the metabolic syndrome in Nonalcohlic fatty liver disease. J Biochem Biophys. 2015;1(2):21–5. Taslima R, Zebunnesa Z, Rahelee Z. Core components of the metabolic syndrome in Nonalcohlic fatty liver disease. J Biochem Biophys. 2015;1(2):21–5.
32.
go back to reference Shen L, Fan J-G, Shao Y, Zeng M-D, Wang J-R, Luo G-H, et al. Prevalence of nonalcoholic fatty liver among administrative officers in shanghai: an epidemiological survey. World J Gastroenterol. 2003;9(5):1106–10.CrossRefPubMedPubMedCentral Shen L, Fan J-G, Shao Y, Zeng M-D, Wang J-R, Luo G-H, et al. Prevalence of nonalcoholic fatty liver among administrative officers in shanghai: an epidemiological survey. World J Gastroenterol. 2003;9(5):1106–10.CrossRefPubMedPubMedCentral
33.
go back to reference Chen SH, He F, Zhou HL, Wu HR, Xia C, Li YM. Relationship between nonalcoholic fatty liver disease and metabolic syndrome. J Dig Dis. 2011;12(2):125–30.CrossRefPubMed Chen SH, He F, Zhou HL, Wu HR, Xia C, Li YM. Relationship between nonalcoholic fatty liver disease and metabolic syndrome. J Dig Dis. 2011;12(2):125–30.CrossRefPubMed
36.
go back to reference Kirovski G, Schacherer D, Wobser H, Huber H, Niessen C, Beer C, et al. Prevalence of ultrasound-diagnosed non-alcoholic fatty liver disease in a hospital cohort and its association with anthropometric, biochemical and sonographic characteristics. Int J Clin Exp. 2010;3(3):202. Kirovski G, Schacherer D, Wobser H, Huber H, Niessen C, Beer C, et al. Prevalence of ultrasound-diagnosed non-alcoholic fatty liver disease in a hospital cohort and its association with anthropometric, biochemical and sonographic characteristics. Int J Clin Exp. 2010;3(3):202.
37.
go back to reference Demirtunc R, Duman D, Basar M, Bilgi M, Teomete M, Garip T. The relationship between glycemic control and platelet activity in type 2 diabetes mellitus. J Diabetes Complicat. 2009;23(2):89–94.CrossRef Demirtunc R, Duman D, Basar M, Bilgi M, Teomete M, Garip T. The relationship between glycemic control and platelet activity in type 2 diabetes mellitus. J Diabetes Complicat. 2009;23(2):89–94.CrossRef
38.
go back to reference Khadka B, Shakya RM, Bista Y. Non-alcoholic fatty liver disease assessment in Nepal. International journal of community medicine and. Public Health. 2017;3(6):1654–9. Khadka B, Shakya RM, Bista Y. Non-alcoholic fatty liver disease assessment in Nepal. International journal of community medicine and. Public Health. 2017;3(6):1654–9.
Metadata
Title
Metabolic syndrome and biochemical changes among non-alcoholic fatty liver disease patients attending a tertiary care hospital of Nepal
Authors
Bashu Dev Pardhe
Shreena Shakya
Anjeela Bhetwal
Jennifer Mathias
Puspa Raj Khanal
Roshan Pandit
Jyotsna Shakya
Hari Om Joshi
Sujan Babu Marahatta
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2018
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/s12876-018-0843-6

Other articles of this Issue 1/2018

BMC Gastroenterology 1/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.